United Kingdom· GB-APID-23973111000001104
Tybost 150mg tablets
A cobicistat product containing cobicistat, registered in United Kingdom by Gilead Sciences Ltd. The same ATC class is registered in 9 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Cobicistat is registered in 9 of 19 countries.
Countries holding a registration under ATC V03AX03 (cobicistat), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 5 of them publish a price we can compare per daily dose
Cobicistat · ATC V03AX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Cobicistat
- Manufacturer
- Gilead Sciences Ltd
- Country
- United Kingdom (GB)
- ATC code
- V03AX03
- ATC class
- Cobicistat
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5391507140876
- gtin05391507145888
- gtin05391507145758
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
541 interactions on record for cobicistat.
Graded by severity as the source publishes them — 243 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cobicistat · interactions on record
541 records
- 243 severe
- 277 moderate
- 21 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- LoperamideA07DA03severe
- EluxadolineA07DA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cobicistat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEvotaz 300 mg - 150 mgBristol-Myers Squibb Pharma
- CzechiaTYBOSTGilead Sciences Ireland UC, Carrigtohill
- SpainTYBOST 150mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FinlandTybostGilead Sciences Ireland UC
- IrelandTybost 150 mg film-coated tabletsGilead Sciences Ireland UC
- NetherlandsTybost 150 mg filmomhulde tablettenGilead Sciences Ireland UC
- PolandTybostGilead Sciences Ireland UC
- SwedenTybost 150 mg Filmdragerad tablettGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tybost
- Liechtenstein · Tybost
- Norway · Tybost
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb5e1079-a319-4ca3-8c3f-91d2304bccbf GET /v1/drugs/fb5e1079-a319-4ca3-8c3f-91d2304bccbf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "23973111000001104",
"desc": "Tybost 150mg tablets (Gilead Sciences Ltd)",
"form": "Oral tablet",
"vpid": "23984211000001104",
"source": "dmd",
"vtm_id": "775341000",
"strength": "150 mg",
"substance": "Cobicistat",
"ingredient": "Cobicistat",
"supplier_code": "2572301000001107"
}See everything about cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.